.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In May 2026, Level operated as a single-category brand with Capsules accounting for 100.0% of sales, while category-level sales fell 61.95% year over year and 17.04% month over month. Despite the category contraction, average price rose 14.50% YoY to $20.02, indicating mix or pack-size shifts within Capsules rather than cross-category migration. With overall brand sales down 61.96% YoY and Capsules carrying the entire mix at 100.0% share, the pattern implies concentration risk: pricing power held on a per-unit basis, but volume declines outweighed it.
The shift toward a higher average price alongside a 17.04% MoM volume pullback suggests that Level’s Capsules positioning is drifting toward a premium or higher-potency stance, trading fewer units at higher price points. Holding the No. 1 rank in Capsules in Nevada during May 2026 while weathering a 61.95% YoY decline and a 17.04% MoM drop implies that share may be maintained through price-led positioning rather than volume-led expansion, a strategy that can preserve rank but compress total throughput if elasticity remains elevated.
Competitive Landscape
Level is ranked #2 in CA Capsules in May 2026, down 1 position year over year, after peaking at #1 in January 2026 and holding #2 for the past three months; meanwhile, Breez sits at #1 with a year-over-year move from #2 to #1 despite a 44.6% YoY sales decline, while ABX / AbsoluteXtracts is #3 with a flat rank versus last year and a 40.0% YoY sales drop. The combination of Level’s slight rank erosion (from #1 YoY to #2 current) alongside competitors holding or improving positions amid double-digit sales contractions implies that Level’s relative share resilience is being tested by category-wide contraction and leaderboard stability, signaling a need to convert its prior January 2026 peak into sustained rank defense.
Notable Products
Protab - Hybrid Extra Strength Tablets 10-Pack (250mg) posted the steepest decline in May 2026 at -47.7% MoM while holding rank 10, paired with Protab - Indica Extra Strength Tablets 10-Pack (250mg) at -46.7% MoM and rank 6, signaling stress in the extra-strength 250mg tier. At the top, Protab - Indica Tablet (100mg) rose 24.9% MoM to rank 1, while Protab - Sativa Profesional Strength Tablet (100mg) slipped -8.6% at rank 2, indicating a mix shift toward lower-dosage 100mg formats over higher-dosage packs. Four of the top ten are Protab+ or Hashtab specialized formulations, yet Protab+ - Lights Out Tablets 10-Pack (50mg CBN, 20mg CBG, 200mg Delta-9 THC, 50mg Delta-8 THC, 20mg THCA) dropped -18.8% at rank 4 alongside Protab+ - THC/THCv/CBG Boost Tablets 10-Pack (200mg THC, 70mg THCv, 30mg CBG) at -12.0% and rank 8, pointing to waning momentum in multi-cannabinoid blends relative to core Protab SKUs. The pattern implies Level is consolidating demand in mainstream 100mg Protab formats while de-prioritizing bulk 250mg and complex blend tablets, a direction that concentrates volume in fewer, simpler dose-led leaders.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
